Nobel Prize in Physiology or Medicine

Clarivate Demonstrates 2021 Nobel Prediction Success in Every Field of Science and Economics

Retrieved on: 
Wednesday, October 13, 2021
Intellectual property, Collection, Paganini Competition, Income, Nobel Prize, Method, Physics, Attention, Nobel Prize in Chemistry, List of Nobel laureates, Citation, Temperature, Committee for the Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel, Economics, Nobel Memorial Prize in Economic Sciences, Clarivate, Unemployment, Terrorism, Nobel, Education, Nobel Prize in Physics, Clarivate Citation Laureates, University, Mark (given name), Invention, Institute, Physiology, Web of Science, Association, Western literature, Hall, Nobel Assembly at the Karolinska Institute, NYSE, Solution, Laureate, Nobel Prize in Physiology or Medicine, Research, Pharmaceutical industry, Palladium

LONDON, Oct. 13, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today celebrates the five new Nobel Laureates across the fields of science and economics who were accurately identified as potential Nobel Prize recipients. Each individual was awarded the designation of Citation Laureate™ as much as 12 years prior to being named by the Nobel Assembly. Clarivate is the only organization in the world to use quantitative data together with expert qualitative analysis to identify the pinnacle realm of scientific contributions recorded in the Web of Science.™ Using this approach, Clarivate identifies researchers 'of Nobel class' and forecasts those who could be awarded the Nobel Prize.

Key Points: 
  • Using this approach, Clarivate identifies researchers 'of Nobel class' and forecasts those who could be awarded the Nobel Prize.
  • The five Citation Laureates named as Nobel Laureates in 2021 are:
    The 2021 Nobel Prize for Physiology or Medicine, awarded to David Julius and Ardem Patapoutian, for their discoveries of receptors for temperature and touch.
  • He is our 60th Nobel awardee and the 16th individual who has gone on to receive a Nobel in the field of Physiology or Medicine.
  • Giorgio Parisi was identified as a potential Nobel honoree by Clarivate just a few weeks ago, in September 2021.

Katalin Karikó named the 2022 recipient of the Pearl Meister Greengard Prize

Retrieved on: 
Friday, October 1, 2021
Metropolitan, National Medal of Science, Nobel Prize, RNA transfection, Partnership, Biomedical Research, Vaccine, RNA, Infection, University, Rockefeller University, DNA, Multimedia, List of life sciences, Pearl Meister Greengard Prize, BioNTech, Biology, Museum, Life, Woman, Neurosurgery, Breakthrough Prize in Life Sciences, COVID-19, Pfizer, Severe acute respiratory syndrome coronavirus 2, Research, Vincent Astor, Lasker Award, Nobel Prize in Physiology or Medicine, Metropolitan Museum of Art, Pharmaceutical industry

NEW YORK, Oct. 1, 2021 /PRNewswire/ --Katalin Karik, whose discovery of how to keep synthetic RNA from activating the innate immune system, paving the way for RNA vaccines including two for SARS-CoV-2, will receive the 2022 Pearl Meister Greengard Prize , The Rockefeller University announced today.

Key Points: 
  • NEW YORK, Oct. 1, 2021 /PRNewswire/ --Katalin Karik, whose discovery of how to keep synthetic RNA from activating the innate immune system, paving the way for RNA vaccines including two for SARS-CoV-2, will receive the 2022 Pearl Meister Greengard Prize , The Rockefeller University announced today.
  • The Pearl Meister Greengard Prize is the preeminent international award recognizing outstanding women scientists.
  • Karik is senior vice president of the biotech company BioNTech and adjunct associate professor of neurosurgery at the University of Pennsylvania.
  • Earlier this month, it was announced that Karik will receive the 2022 Breakthrough Prize in Life Sciences.

Juntendo University research: Emergence of malaria-drug resistance in Africa

Retrieved on: 
Thursday, September 23, 2021
Vomiting, Blood, Nobel Prize, Parasitism, The New England Journal of Medicine, Patient, World, Plasmodium, Plasmodium falciparum, Half-life, Death, Jaundice, World Health Organization, Nausea, Anemia, Fatigue, Disease, Risk, Drug resistance, Juntendo University, Headache, Human, Nobel Prize in Physiology or Medicine, Fever, Myalgia, Artesunate, Genotype, Chills, Skin, Diarrhea, Pharmaceutical industry, Vaccine

TOKYO, Sept. 23, 2021 /PRNewswire/ -- Ninety percent of global malaria cases and deaths are reported in Africa.

Key Points: 
  • TOKYO, Sept. 23, 2021 /PRNewswire/ -- Ninety percent of global malaria cases and deaths are reported in Africa.
  • The evidence of Mita and colleagues regarding A675V implies that its status should be updated to that of a proper molecular resistance marker.
  • The results of Mita and colleagues clearly demonstrate the independent emergence of artemisinin-resistant P. falciparum in Africa, which, quoting the scientists, "poses a potential risk of cross-border spread across Africa, highlighting the need to perform large-scale surveys."
  • The advantage of artemisinin and its derivatives for treating malaria over other drugs is that they quickly kill all of a parasite's life cycles.

Juntendo University research: Emergence of malaria-drug resistance in Africa

Retrieved on: 
Thursday, September 23, 2021
Vomiting, Blood, Nobel Prize, Parasitism, The New England Journal of Medicine, Patient, World, Plasmodium, Plasmodium falciparum, Half-life, Death, Jaundice, World Health Organization, Nausea, Anemia, Fatigue, Disease, Risk, Drug resistance, Juntendo University, Headache, Human, Nobel Prize in Physiology or Medicine, Fever, Myalgia, Artesunate, Genotype, Chills, Skin, Diarrhea, Pharmaceutical industry, Vaccine

TOKYO, Sept. 23, 2021 /PRNewswire/ -- Ninety percent of global malaria cases and deaths are reported in Africa.

Key Points: 
  • TOKYO, Sept. 23, 2021 /PRNewswire/ -- Ninety percent of global malaria cases and deaths are reported in Africa.
  • The evidence of Mita and colleagues regarding A675V implies that its status should be updated to that of a proper molecular resistance marker.
  • The results of Mita and colleagues clearly demonstrate the independent emergence of artemisinin-resistant P. falciparum in Africa, which, quoting the scientists, "poses a potential risk of cross-border spread across Africa, highlighting the need to perform large-scale surveys."
  • The advantage of artemisinin and its derivatives for treating malaria over other drugs is that they quickly kill all of a parasite's life cycles.

Koji Tanabe, CEO of I Peace, Inc. honored by World Biz Magazine with "Top 100 Innovation CEO" Award

Retrieved on: 
Tuesday, September 21, 2021
Nobel Prize, Ministry, CGMP, Japan Society for the Promotion of Science, List of health departments and ministries, Stanford University, Editorial board, Patient, Multimedia, Institute, Kyoto University, Blood, Adult, CEO, Life, Stanford University School of Medicine, PALO, Technology, View, Peace, Research, Potency (pharmacology), Regenerative medicine, Nobel Prize in Physiology or Medicine, Welfare, Quality of life, Social responsibility, B cell, Industry, IPSC, Pharmaceutical industry, Medical device

He founded I Peace, Inc. in 2015, aiming to transform iPSCs as a research tool to an essential commodity of life.

Key Points: 
  • He founded I Peace, Inc. in 2015, aiming to transform iPSCs as a research tool to an essential commodity of life.
  • World Biz Magazine's Top 100 Innovation CEO Awards celebrates business leaders across the globe that are making major strides in their industries.
  • We pride ourselves on delivering a high quality readership experience - packed with intelligent articles combined with energizing CEO interviews.
  • World Biz Magazine aims to provide C-Suite stake-holders with information that will drive their business success while serving as a forum for collaboration on innovation and social responsibility.

Pamela Björkman wins the 2021 Pearl Meister Greengard Prize

Retrieved on: 
Friday, September 17, 2021
Metropolitan, Biochemistry, Nobel Prize, California, American Academy of Arts and Sciences, Harvard University, Pearl Meister Greengard Prize, Partnership, Biomedical Research, Protein, Woman, Vincent Astor, National academy, NIH Director's New Innovator Award, Rockefeller University, American, Virus, Immune system, Museum, Crystallography, Autoimmunity, American Academy, National Medal of Science, Life, Max Planck, COVID-19, National, American Philosophical Society, Pioneer Award, Severe acute respiratory syndrome coronavirus 2, Spelman College, Research, Infection, NIH, Nobel Prize in Physiology or Medicine, HIV, Metropolitan Museum of Art, Pharmaceutical industry

NEW YORK, Sept. 17, 2021 /PRNewswire/ -- Renowned biochemist Pamela J. Bjrkman will receive the 2021 Pearl Meister Greengard Prize , the preeminent international award recognizing outstanding women scientists.

Key Points: 
  • NEW YORK, Sept. 17, 2021 /PRNewswire/ -- Renowned biochemist Pamela J. Bjrkman will receive the 2021 Pearl Meister Greengard Prize , the preeminent international award recognizing outstanding women scientists.
  • "The Pearl Meister Greengard Prize shines a spotlight on extraordinary women who have made fundamental contributions to science."
  • says Michael W. Young , Richard and Jeanne Fisher Professor and Vice President of Academic Affairs at Rockefeller, Nobel Laureate, and chair of the Pearl Meister Greengard Prize selection committee.
  • Register here to attend the Pearl Meister Greengard Prize virtual ceremony and learn more about the award.

DGAP-News: Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck

Retrieved on: 
Wednesday, September 8, 2021

Merck has completed a multi-institutional Phase I trial led by Apostolia-Maria Tsimberidou, M.D., Ph.D., professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Key Points: 
  • Merck has completed a multi-institutional Phase I trial led by Apostolia-Maria Tsimberidou, M.D., Ph.D., professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
  • Combined with trastuzumab or tamoxifen, DIACC3010 demonstrated early signs of antitumor activity in patients with advanced breast cancer resistant to multiple standard therapies.
  • "We are very proud that, after a highly competitive selection process, Merck has chosen Diaccurate to bring DIACC3010 into advanced clinical development", said Dominique Bridon, Ph.D., CEO of Diaccurate.
  • As part of its plan to develop DIACC3010, Diaccurate has designed an extensive PoC clinical program exploring both incurable solid tumors and refractory hemato-oncology indications.

The Oligonucleotide Therapeutics Society Presents the 2021 Virtual Conference

Retrieved on: 
Saturday, September 4, 2021
Nucleic acids, Branches of biology, Biology, RNA, Molecular biology, Small interfering RNA, Silence Therapeutics, RNA interference, Alnylam Pharmaceuticals, Sense, Intellia Therapeutics

SAN DIEGO, Sept. 04, 2021 (GLOBE NEWSWIRE) -- The Oligo Meeting is purposefully designed to bring people together to share incredible advancements in the field of oligonucleotide therapeutics.

Key Points: 
  • SAN DIEGO, Sept. 04, 2021 (GLOBE NEWSWIRE) -- The Oligo Meeting is purposefully designed to bring people together to share incredible advancements in the field of oligonucleotide therapeutics.
  • Last year's virtual meeting was extraordinarily successful, and this year's virtual conference has been carefully planned to be even more seamlessly engaging and productive.
  • Recorded talks and posters can be viewed on-demand through December 31, 2021, for all registered delegates.
  • Last year's virtual conference received rave reviews from participants and this year's virtual meeting is expected to be even more spectacular.

Seoul Semiconductor Expands Its Business Through SunLike Natural Sunlight Spectrum LED Technology Patents and Business Rights Transfer

Retrieved on: 
Wednesday, September 1, 2021
Other Manufacturing, Optical, Hardware, Health, Technology, Semiconductor, Manufacturing, Other Health, Sunlight, LED, AC, UV, Main sequence, Sleep, CES, Lighting, Memory, DNA, Medicine, KOSDAQ, Health, Seoul Semiconductor, Semiconductor, Cell, Circadian rhythm, Learning, Nobel Prize, Myopia, CEO, HCL, Exhibition, Infradian rhythm, USD, Nobel Prize in Physiology or Medicine, Patent, Technology, Television

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that it expects to expand its business of SunLike natural sunlight spectrum LED technology optimized for natural human biological rhythm which has 24-hour cycle, as the transfer of patent rights and business rights of SunLike LED technology has been completed from Toshiba Materials Co., Ltd. (CEO Katsuaki Aoki, Yokohama), which has jointly developed SunLike technology.

Key Points: 
  • Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that it expects to expand its business of SunLike natural sunlight spectrum LED technology optimized for natural human biological rhythm which has 24-hour cycle, as the transfer of patent rights and business rights of SunLike LED technology has been completed from Toshiba Materials Co., Ltd. (CEO Katsuaki Aoki, Yokohama), which has jointly developed SunLike technology.
  • SunLike is a LED technology that reproduces the sunlight spectrum (all natural colors such as red, orange, yellow, blue and navy) curve.
  • With SunLike technology, Seoul Semiconductor believe that the technology supports to reduce myopia and helps people fall a sleep well at night when cells are regenerated.
  • Seoul Semiconductor is the worlds second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents.

Zhong Ji Longevity Science Announces 2021 Interim Results

Retrieved on: 
Tuesday, August 31, 2021
Cloud, MOU, Science, Research, Health, Awareness, Board, Risk, Partnership, Solution, Longevity, Seemabaddha, Ecosystem, Thermo Fisher Scientific, Health care, Vitamin C, Software, China Biologic Products, Consultant, Master, Investment, Martin Yan, VC, Nobel Prize in Physiology or Medicine, Technology, Industry, MSC, Incidence, Review, R, The Group, Tablet, NK, Biotechnology, Mortality, FDA, NMN, Growth, Cancer, Acquisition, Period, Marketing, National Healthcareer Association, CBNK, COVID-19, Property management, Management, Pharmaceutical industry

HONG KONG, Aug 31, 2021 - (ACN Newswire) - Zhong Ji Longevity Science Group Limited ("Zhong Ji Longevity Science", together with its subsidiaries, the "Group"; stock code: 0767.HK) is pleased to announce its unaudited interim results for the six months ended 30 June 2021 ("Period under Review").

Key Points: 
  • HONG KONG, Aug 31, 2021 - (ACN Newswire) - Zhong Ji Longevity Science Group Limited ("Zhong Ji Longevity Science", together with its subsidiaries, the "Group"; stock code: 0767.HK) is pleased to announce its unaudited interim results for the six months ended 30 June 2021 ("Period under Review").
  • Mr. YAN Li, Chairman of the Board and Executive Director of Zhong Ji Longevity Science, said, "Since the change of company name, the Group has been focusing on expanding its longevity science business.
  • It is expected that longevity science industry will embrace bright prospects, leading the development of Zhong Ji Longevity Science to bear fruits in future.
  • Zhong Ji Longevity Science Group Limited (0767.HK) is principally engaged in longevity science, money lending, securities and other investments, financial and investment advisory, as well as property investment.